A bibliometric review of chimeric antigen receptor T cell therapy (CAR-T) in the treatment of multiple myeloma (2013–2025)

This study employed bibliometric techniques to evaluate the current status and emerging trends in the application of chimeric antigen receptor T cell (CAR-T) therapy for the treatment of multiple myeloma (MM). Relevant literature from 2013 to 2025 was extracted from the Web of Science Core Collection database. Analytical tools such as CiteSpace and VOSviewer were utilized to examine annual publication volume, authorship, institutional contributions, geographical distribution, funding sources, journal impact, and keyword trends. The analysis included a total of 1313 pertinent publications. Since 2019, there has been a significant surge in both the annual publication volume and citation frequency in this domain. The United States leads in terms of publication volume, total citations, H-index, and centrality, while China ranks second globally in publication volume. Initial research concentrated on fundamental immunotherapies and targets; however, recent studies have shifted towards validating the clinical efficacy of CAR-T therapy and have expanded to address complex clinical challenges such as patient management, mechanisms of drug resistance, and toxicity. CAR-T therapy is a rapidly developing interdisciplinary research area in the field of MM. Future research should focus on solving core issues faced in clinical applications, such as drug resistance, toxicity management, and efficacy improvement.